Home > Back to Publisher > Report Information

Automated and Rapid Microbiological Tests

Global Industry Analysts
October 1, 2011
660 Pages - SKU: GJOB6710953

Abstract Table of Contents Related Reports

Countries covered: United States, Global

This report analyzes the worldwide markets for Automated and Rapid Microbiological Tests in US$ Million by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 93 companies including many key and niche players such as Abbott Laboratories, Abbott Diagnostics, Alere Inc., Becton Dickinson and Company, bioMerieux SA, bioMerieux, Inc., Bio-Rad Laboratories, Inc., Cellabs Pty Ltd, Celsis International Plc., Coris BioConcept, F. Hoffmann-La Roche Ltd., Gen-Probe Inc., MedMira Inc., Meridian Biosciences, Inc., Orasure Technologies, Inc., Orion Diagnostica Oy, Quidel Corporation, Sekisui Diagnostics, Siemens Healthcare Diagnostics, Inc., Thermo Fisher Scientific, Inc., Remel, Inc., and Oxoid Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Data Interpretation & Reporting Level; Product Definitions and Scope of Study
2. INDUSTRY OVERVIEW: Outlook; Macro: The Big Picture; Market Structure
3. MARKET TRENDS & ISSUES: Advancements in Molecular Diagnostics - A Boon or a Threat; Leading Companies in Molecular Diagnostics Market; Antibiotic Resistant Bacteria Throws the Spotlight On Microbial Testing; Instant Detection of Pathogens - A New Epoch in the Fight for Survival; Lower Cost Rapid Tests Built on Multiple Sampling Modalities - Gaining Momentum; “Time Constraints?” - Rapid Tests to the Rescue; Rapid HIV Tests: A New Age Diagnostic Weapon Against the Killer Disease; Accuracy/Reliability of Home HIV Testing: A Bone of Contention; Development of Near Patient Test Kits: A Market Driven Phenomenon; Near Patient Test Kits: A Rumination of Possibilities; Automated Blood Culture Systems: A Winning Edge in the Fight Against Bacteremia; Leading Food Processors Resort to Rapid Microbiological Testing; Impact of Food Scares on Rapid Microbiological Tests Market; Demand for Microbiological Tests & Level of QC in the Food Industry; Rapid Tests Creating Brighter Avenues in Food Microbiology Testing Market; Dire Need to Nip Operating Costs Throws the Spotlight on Rapid Tests; Key Advantages/Benefits of Rapid Microbiological Tests on Food; Food Packages of the Future Ingrained with Microbial Alert Systems; Technology Innovations in Rapid Food Microbial Testing: A Historic Brief; Obtaining Regulatory Approval - A Major Non-Technical Hindrance
4. FACTORS INFLUENCING THE MARKET: Continuing Biological Warfare with Pathogens Sparks Market Growth; Innovative Products - A Key Growth Strategy; Other Market Drivers in a Capsule; Validation of Rapid Microbiological Tests: An Imperative Prerequisite; Non-Conformance to Testing Requirements: A Weighty Concern; Influenza - Boosting Rapid Test Prospects
5. PRODUCT/TECHNOLOGY OVERVIEW: Automated & Rapid Microbiological Tests: A Definition; Benefits of Automated & Rapid Microbiological Tests; Classification of Rapid Microbiological Test Methods; How Does a Rapid Test Work?; Sample Preparation - A Key Procedure; Automated Identification and Susceptibility Systems; Automated Blood Culture Systems; Automated Tuberculosis Systems; Microminiaturization of Diagnostic Tests: How Is It Effected?; Acid-Fast Microscopy - The Forerunner of Rapid Tests; Gram's Stain: A Time-Honored & Rapid Method to Detect Pathogens in Blood; Enabling Technologies of Automated & Rapid Microbiological Tests
6. END-USE APPLICATION ANALYSIS: Applications in Clinical Investigations; Respiratory Rapid Tests; Applications in Non-Clinical Investigations
7. PRODUCT INNOVATIONS/INTRODUCTIONS: BioControl Systems Develops PCR for Detecting Non-O; Serotypes of STEC; InDevR Introduces New Virus Counter; MicroPhage Receives Approval from FDA for KeyPath™ MRSA/MSSA Blood Culture Test - BT; Health Canada Approves DuPont’s BAX® System Real-Time Assay; Neogen Receives Approval from AOAC for Reveal 2.0 Test; Life Technologies and University of Pennsylvania School of Veterinary Medicine Introduce TaqMan® Salmonella enteritidis Detection Kit; AdvanDX Obtains 510(k) Clearance from US FDA for GNR Traffic Light™ PNA FISH®; Pall Introduces GeneDisc Rapid Microbiology System; Abbott Laboratories Introduces PLEX-ID™ Biothreat Assay; bioMerieux Receives FDA Clearance for NucliSENS EasyQ MRSA; BD Launches BD Max™ Open System; Luxcel Biosciences and Mocon Develop GreenLight™900 Series; Bruker Launches pTD™ for Homeland Security; Hygiena International Launches EnSURE; Researchers at University of Georgia Develop Pneumonia Diagnostic Test; BD Diagnostics Obtains Approval from FDA for BD MAX™ GBS Assay; bioMérieux Receives Approval for TEMPO® STA from AOAC and AFNOR; Bruker Introduces MALDI Sepsityper™ Kit; AdvanDx Introduces GNR Traffic Light™ PNA FISH®; ZyGEM Launches Microbial Fingerprinting Diagnostic Technology; BD Diagnostics Launches BD BACTEC™ MGIT™ 320 Mycobacteria Culture System; Particle Measuring Systems Launches BioLaz™ Real-Time Microbial Monitor; NanoLogix Launches Quick-Test Product Line; MOCON Introduces GreenLight™ Screening System; Life Technologies Unveils MicroSEQ® Rapid Microbial Identification System; IDEXX Laboratories Launch Enterolert®-DW in Europe; Alere Rolls Out three Cardiac Testing Solutions; Millipore Introduces New Milliflex Quantum Rapid Microbiological Test Method; BD Diagnostics Adds Automated Microbiology Specimen Processor to its Diagnostic Portfolio; Roche Introduces New Automatic Clinical Laboratory System, Cobas®; Thermo Fisher Scientific Launches an Automated Photometric Method; Thermo Fisher Scientific Introduces Salmonella Rapid Culture Method; BD Receives FDA Clearance for BD ProbeTec Amplified DNA Assays on BD Viper System; Oxoid Introduces Xpect® Flu A&B; Oxoid Extends ProSpecT Range; Oxoid Launches ELISA Systems Test Kits Range; Oxoid Introduces Brilliance VRE Agar and Brilliance ESBL Agar; Oxoid Launches RapID Kits; Inverness Medical Innovations Introduces C. DIFF QUIK CHEK COMPLETETM Rapid Test; Celsis International Launches Celsis ReACTTM; Roche Diagnostics Introduces LightCycler® Mycobacterium Detection Kit; bioMérieux Introduces NucliSENS EasyQ® HIV-1 v2.; Celsis International Unveils RapiScreenTM Beverage; Siemens Launches MicroScan Synergies plus® gram-positive ID/MIC and MIC Combination Panels; Oxoid Introduces IDEIATM Norovirus; Oxoid Introduces Salmonella PrecisTM Process; Remel Offers FDA Approved RPMI 1640 Agar w/MOPS and 2% Glucose; Oxoid Launches Rapid MDG Broth; Lonza Introduces microCompass TYMC (Total Yeast and Mould Count) Detection Kit; Inverness Medical Introduces Determine HIV-1/2 Ag/Ab Combo; Meridian Bioscience Rolls Out Two New Rapid Tests for Detecting Epstein-Barr Virus; Oxoid Introduces Staph Plus System for Identifying Staphylococcal Species
8. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST - A PERSPECTIVE BUILDER: Siemens Healthcare Diagnostics Launches MicroScan® WalkAway® plus Diagnostic Microbiology Systems; Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect™ test, in US; bioMérieux Introduces VIDAS®, an automated Clostridium difficile A & B Toxins Detection Test; Oxoid Launches Remel Wellcolex® Colour Tests for Testing Shigella, E. coli O157 and Salmonella; Siemens Healthcare Diagnostics Obtains Health Canada Approval for its VERSANT 440 Molecular System; Oxoid Unveils Remel Xpect™ Clostridium Difficile Toxin A/B Test; Neogen Introduces Soleris System; ATCC Introduces Authenticult™ Quality Control Microbiological Testing Tool; Bio-Rad Introduces New EBV Kits; Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test; Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test; FDA Clears Usage of TIGRIS® System for Testing WNV in Donated Blood; FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli Infection; bioMérieux Introduces TEMPO® Quality Indicator Testing System; Biotrace Introduces Tecra Unique Campylobacter Rapid Test; bioMérieux Introduces TEMPO® EB test for Enterobacteriaceae; Roche Unveils Elecsys TORCH Assays; Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan; bioMérieux Develops Advanced Colorimetry™ NH Card; Roche Introduces Rapid LightCycler SeptiFast Sepsis Test across EU; Oxoid Launches New Rapid Test for Salmonella Detection in Food Products; Oxoid Unveils New Contact Plate Design; FDA Approves Fluconazole Susceptibility Tests from BioMérieux; Polysciences Unveils New Microbiological & Bacterial Detection Applications; Researchers Develop New Rapid MODS Test for TB Detection; Dade Behring Unveils Automated Quadriga BeFree System; FDA Approves Abbott PRISM® HBsAg Assay; Bayer’s EHIV Test Receives FDA Clearance; Gen-Probe Obtains FDA Approval to Use Aptima Test on Additional Specimens; Roche Diagnostics’ cobas TaqScreen MPX Test Receives CE Mark Approval; Cepheid Introduces Rapid Xpert® MRSA Test in Europe; Bio-Rad Widens Culture Media with Addition of RAPID'Salmonella; Chemogen Develops New Tuberculosis Rapid Test; bioMerieux Rolls Out VIDAS® LDUO Test; Zonda Develops New Rapid Test for Chlamydia; MedMira Launches MiraCare Rapid HIV Test; STMicroelectronics and Mobidiag Unveil Lab-On-Chip; Vermicon Launches ScanVIT-Legionella Rapid Test Kit; New Line of Rapid Microbial Detection Systems from Centrus; OraSure Rolls Out OraQuick ADVANCE; Abbott Unveils Automated HCV Test; ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and Respiratory Pathogens; Biophage Pharma Offers Service for Microbiological Testing; bioMerieux Releases New Rapid Test for Nosocomial Infections; bioMerieux Widens Product Portfolio with Addition of TEMPO® System
9. RECENT INDUSTRY ACTIVITY: Sekisui Chemical Acquires Diagnostic Products Business of Genzyme; Dynacare Laboratories Acquires Bruker MALDI Biotyper System; Magellan Biosciences Enters into Partnership with miacom Diagnostics; Lonza Signs Distribution Agreement with Roche; BD Enters into Collaboration with Bruker Daltonics; Seegene Enters into Partnership with Molzym; bioMérieux Enters into Partnership with Shanghai Institutes for Biological Sciences; Becton, Dickinson and Company Acquires Global Rights to Market Micro PRO; Rapid Micro Biosystems Enters Into Partnership with Life Technologies; DuPont and U.S. Department of Agriculture to Collaborate for New Microbiological Test; bioMérieux and Biocartis Enter into Partnership; BD Diagnostics Collaborates with Lonza Group; Rapid Micro Biosystems Signs Contract with BARDA; Shimadzu and bioMérieux Enter into Partnership; Micro Identification Technologies and OSI Optoelectronics Sign Agreement; Inverness Medical Adopts New Corporate Identity; Thermo Fisher Acquires Ahura Scientific; Don Whitley Signs Distribution Agreement with Zisys; Charm Sciences Acquires MLX Microplate Luminometer Product Line from Dynex Technologies; Alpha Analytical Acquires Boston Analytical Inc.; Roche Group Acquires Genentech; Roche Acquires Innovatis AG; 3M Takes Over Biotrace International; Lab21 Buys Majority Stake in Biotec Laboratories; Vacci-Test Acquires Maxivet; bioMerieux Acquires PML Microbiologicals; 3M Acquires Food Diagnostics AS; Becton, Dickinson and Company Receives License for its GeneOhmTM from Health Canada; BD Diagnostics Receives CE Marking for BD GeneOhmTM VanR Test; bioMérieux Bags AOAC Research Institute's Performance- Tested Methods SM Approval; MedMira Receives Sales Approval of Multiplo HBV/HIV/HCV Rapid Tests Market; Schering-Plough Inks International Collaboration Agreement with OraSure Technologies; Roche Selects Quidel's Influenza Test; Quidel Enters into Global Alliance with bioMerieux; Premier's QUEST Selects Remel SpectraTM MRSA; Thermo Fisher Scientific and MedAssets Supply Chain Systems Enter into a Supply Agreement; Thermo Fisher Scientific Bags FDA Approval for SpectraTM MRSA; Advantest to Take Over Credence Systems; DSM Food Specialties to Acquire CMT Srl; Sysmex Signs Agreement with bioMerieux; Nanogen Enters into Definitive Agreement with Elitech Group; Silliker Acquires Majority Stake in EGI Laboratory; BD Establishes New Rapid Diagnostic Products Manufacturing Facility in China; Quidel Corporation Obtains CLIA Waiver from US FDA for its QuickVue(R) RSV Test; Siemens Obtains US FDA Approval for its VERSANT™ 440 Molecular System; bioMérieux to Market Wescor’s Customized Slide Stainer Instruments under bioMérieux Brand; Schering-Plough and OraSure Ink Collaboration Agreement for Developing Rapid Oral HCV Test; Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-II Blood Screening Test; Quidel and bioMérieux Form a Long-term Alliance in Rapid Diagnostic Tests; BD Diagnostics Obtains US FDA Approval for BD GeneOhm™ StaphSR Assay
10. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER: Siemens Acquires Dade Behring; Concateno Acquires Euromed; Meridian Bioscience Obtains US FDA Approval for Two New Rapid Tests; Thermo Fisher Scientific Teams Up with KBA for Expanding its Microbiology Business Division in Lenexa; OraSure and SCMS Enter into an Agreement for Supplying OraQuick(R) HIV Test to PEPFAR Countries; Abbott Obtains US FDA Approval for its Fully Automated PRISM® HCV Test; Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS® System for Testing Donated Blood; AdvanDx Ropes In bioMérieux for Distributing its Rapid Diagnostic Tests in US; 3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests For Detecting HAIs; Gen-Probe’s PROCLEIX® TIGRIS® System Obtains US FDA Approval for Screening Donated Blood for West Nile Virus; 3M Acquires Acolyte Biomedica; Formation of Siemens Medical Solutions Diagnostics; bioMérieux Bags Contract to Provide VITEK® 2 System for Scottish NHS Labs; bioMérieux Licenses NorChip’s HPV Test Technology for Cervical Cancer; bioMérieux in Strategic Agreement with Cepheid for Sepsis Assays; 3M Health Care Creates New Medical Diagnostics Unit; Schering-Plough & OraSure to Develop Rapid Oral HCV Test; 3M Acquires Biotrace International; Siemens Acquires DPC; Oxoid Acquires Microbiology Business Activities of Dako; Inverness Acquires IDT and Thermo BioStar; BMD in Agreement with MND for Research on Diagnostic Tests; Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus Detection Test; Dutch Government Grants €7.9 Million to FIND; FIND and Hain to Develop Rapid Test for MDR and XDR TB; 3M & Gen-Probe Ally for Developing Rapid Molecular Tests for Food Safety; Bio View Inks Three-Year Distribution Agreement with Abbott Molecular; Bodycote Acquires Foodscan Laboratories; Cepheid Bags STTR Funding for Development of Rapid TB Test; Abbott and Verax in Distribution Agreement for Verax Platelet PGD® Test; BSL Supplies ABBOTT PRISM® System to Blood Donor Testing Centers; Abbott & ARC in Agreement for Automated Blood Screening Tests; BD to Set Up Production Facility for Rapid Diagnostic Products in China; BD Diagnostics Delivers STI Testing Products to BioReference; Meridian Licenses LAMP Diagnostic Test Technology from Eiken; OraSure Inks Multi-Year Purchase Contract with New York City; Abbott Inks Single-Source Agreement with Novation for HIV Test; Neogen Takes Over Centrus International; Becton, Dickinson and Company Acquires GeneOhm Sciences; Inverness Medical Innovations Makes a Synergetic Purchase of ACON Laboratories; Quest Diagnostics Strikes Deal with BD Diagnostics; Novation Inks Pact with Abbott for Rapid HIV-1/; Antibody Test; TREK Diagnostic and Novation Inks Agreement; Clinton Foundation Inks Agreement with Four Companies to Cut Prices; Chembio Obtains FDA Approval for HIV 1/2 Stat-Pak and Sure Check HIV 1/2 Rapid Test PMAs; Roche’s LightCycler SeptiFast Test Attains CE Mark; Zonda Expands Distribution of Products in Europe; OraSure Wins Rapid HIV Tests Order; MedMira Secures Orders for Rapid HIV Tests; Cepheid Collaborates with Foundation for Innovative Diagnostics; Chembio Obtains Clearance for Rapid HIV Tests in Kenya; Genesis Bioventures Bags US Patent for Rapid Prion- Detection Assay; MedMira Obtains CE Mark for MiraCare; Setema to Distribute Chembio’s Rapid HIV Tests in Ethiopia; Clinton Foundation HIV/AIDS Initiative Selects Chembio to Provide Rapid HIV Tests; Quidel Acquires immunochemical Fecal Occult Blood Test; Xact Aid Snaps Up STD Alert; Grant Life Sciences Acquires Rapid Tests from AccuDx; Millipore Ties Up with Gen-Probe; Foundation for Innovative New Diagnostics forms Collaboration with Eiken Chemical; WayPoint and Global Rapid Diagnostic Leader Enter into an Agreement; Akers Biosciences Enters into a Distribution Agreement with Alco Industries; Celsis and BioVentures Enter into Licensing Agreement; Thermo Electron Inks Pact with Genomic Profiling Systems; Abbott and OraSure Enters into Agreement for OraQuick ADVANCE Rapid HIV-1/2 Test; bioMérieux Signs Agreement with Novel Diagnostics; Dade Behring Bags FDA Approval for Antimicrobial Susceptibility Test Panels; OraSure Bags HCV Patent License from Chiron and Ortho- Clinical Diagnostics; BD Diagnostics Receives FDA Approval for BD Directigen™ EZ Flu A+B Test; BD Diagnostics Bags FDA Clearance for BBL™ CHROMagar™ MRSA Product; MedMira Obtains Rights to Market Rapid HIV Tests in Guizhou Province, China; Gen-Probe Obtains FDA Clearance for PROCLEIX® West Nile Virus Assay; Medical Services International Secures Clearance for Rapid Test Kits; Medical Services International Receives Exclusive Marketing Rights for TB Test Kit; Adaltis Receives Orders for HIV Rapid Tests from China; MedCap Bags Exclusive Distribution Rights for Syphilis Rapid Test; Genomic Profiling Systems Obtains NIAID Funds to Develop Testing Platform; Gen-Probe Obtains US Patent for Automated Process for Nucleic Acid Testing; Bio-Rad Receives Approval for HIV-1/HIV-; Rapid Test
11. FOCUS ON SELECT GLOBAL PLAYERS: Abbott Laboratories (USA); Alere Inc. (US); Becton Dickinson and Company (USA); bioMerieux SA (France); bioMerieux, Inc. (USA); Bio-Rad Laboratories, Inc (USA); Cellabs Pty Ltd (Australia); Celsis International Plc (UK); Coris BioConcept (Belgium); F. Hoffmann-La Roche Ltd. (Switzerland); Gen-Probe Inc. (USA); MedMira, Inc. (Canada); Meridian Biosciences, Inc. (USA); Orasure Technologies, Inc. (USA); Orion Diagnostica Oy (Finland); Quidel Corp. (USA); Sekisui Diagnostics (Japan); Siemens Healthcare Diagnostics, Inc. (USA); Thermo Fisher Scientific, Inc. (USA); Remel, Inc. (USA); Oxoid Limited (UK)
12. GLOBAL MARKET PERSPECTIVE: Table 7: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests by Geographic Region - US, Europe, and Rest of World IndependentlyAnalyzed with Annual Revenues in US$ Million for Years2009 through 2017(includes corresponding Graph/Chart); Table 8: World Historic Review for Automated and Rapid Microbiological Tests by Geographic Region - US, Europe,and Rest of World Independently Analyzed with AnnualRevenues in US$ Million for Years 2003 through 2008(includes corresponding Graph/Chart); Table 9: World 15-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of Worldfor Years 2003, 2010 & 2017 (includes correspondingGraph/Chart); Table 10: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, andRest of World Independently Analyzed with AnnualRevenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart); Table 11: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World IndependentlyAnalyzed with Annual Revenues in US$ Million for Years2003 through 2008 (includes corresponding Graph/Chart); Table 12: World 15-Year Perspective for Automated andRapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenuesfor US, Europe, and Rest of World for Years 2003, 2010 &2017 (includes corresponding Graph/Chart); Table 13: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal InfectionRapid Tests, GC/Chlamydia Rapid Tests and OtherAutomated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million forYears 2009 through 2017 (includes correspondingGraph/Chart); Table 14: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by EquipmentUsed - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid MicrobiologicalTests Independently Analyzed with Annual Revenues inUS$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart); Table 15: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by EquipmentUsed - Percentage Breakdown of Revenues for Automated Identification & Susceptibility Systems, Automated BloodCulture Systems, Automated Tuberculosis Systems,Streptococcal Infection Rapid Tests, GC/ChlamydiaRapid Tests and Other Automated & RapidMicrobiological Tests for Years 2003, 2010 &2017 (includes corresponding Graph/Chart); Table 16: World Recent Past, Current & Future Analysisfor Automated Identification & Susceptibility Systems inClinical Applications by Geographic Region - US, Europe,and Rest of World Independently Analyzed with AnnualRevenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart); Table 17: World Historic Review for AutomatedIdentification & Susceptibility Systems in ClinicalApplications by Geographic Region - US, Europe,and Rest of World Independently Analyzed withAnnual Revenues in US$ Million for Years 2003through 2008 (includes correspondingGraph/Chart); Table 18: World 15-Year Perspective for AutomatedIdentification & Susceptibility Systems in ClinicalApplications by Geographic Region - PercentageBreakdown of Revenues for US, Europe, andRest of World for Years 2005, 2010 & 2015(includes corresponding Graph/Chart); Table 19: World Recent Past, Current & Future Analysisfor Automated Blood Culture Systems in Clinical Applicationsby Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$Million for Years 2009 through 2017(includescorresponding Graph/Chart); Table 20: World Historic Review for Automated BloodCulture Systems in Clinical Applications by GeographicRegion - US, Europe, and Rest of World IndependentlyAnalyzed with Annual Revenues in US$ Million forYears 2003 through 2008 (includes correspondingGraph/Chart); Table 21: World 15-Year Perspective for Automated Blood Culture Systems in Clinical Applications by GeographicRegion - Percentage Breakdown of Revenues for US,Europe, and Rest of World for Years 2003, 2010 &2017 (includes corresponding Graph/Chart); Table 22: World Recent Past, Current & Future Analysis for Automated Tuberculosis Systems in Clinical Applicationsby Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$Million for Years 2009 through 2017(includescorresponding Graph/Chart); Table 23: World Historic Review for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed withAnnual Revenues in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart); Table 24: World 15-Year Perspective for AutomatedTuberculosis Systems in Clinical Applications byGeographic Region - Percentage Breakdown ofRevenues for US, Europe, and Rest of World forYears 2003, 2010 & 2017 (includes correspondingGraph/Chart); Table 25: World Recent Past, Current & Future Analysis for Streptococcal Infection Rapid Tests in Clinical Applicationsby Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$Million for Years 2009 through 2017(includescorresponding Graph/Chart); Table 26: World Historic Review for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region -US, Europe, and Rest of World Independently Analyzedwith Annual Revenues in US$ Million for Years 2003through 2008 (includes corresponding Graph/Chart); Table 27: World 15-Year Perspective for StreptococcalInfection Rapid Tests in Clinical Applications byGeographic Region - Percentage Breakdown of Revenuesfor US, Europe, and Rest of World for Years 2003, 2010 &2017 (includes corresponding Graph/Chart); Table 28: World Recent Past, Current & Future Analysisfor GC/Chlamydia Rapid Tests in Clinical Applicationsby Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$Million for Years 2009 through 2017(includescorresponding Graph/Chart); Table 29: World Historic Review for GC/ChlamydiaRapid Tests (*) in Clinical Applications by GeographicRegion - US, Europe, and Rest of World IndependentlyAnalyzed with Annual Revenues in US$ Million forYears 2003 through 2008 (includes correspondingGraph/Chart); Table 30: World 15-Year Perspective for GC/ChlamydiaRapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, andRest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart); Table 31: World Recent Past, Current & Future Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, andRest of World Independently Analyzed with AnnualRevenues in US$ Million for Years 2009 through2017 (includes corresponding Graph/Chart); Table 32: World Historic Review for Other Automated &Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenuesin US$ Million for Years 2003 through 2008(includes corresponding Graph/Chart); Table 33: World 15-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenuesfor US, Europe, and Rest of World for Years 2003,2010 & 2017 (includes corresponding Graph/Chart); Table 34: World Recent Past, Current & Future Analysisfor Automated and Rapid Microbiological Tests inNon-Clinical Applications by Geographic Region -US, Europe, and Rest of World IndependentlyAnalyzed with Annual Revenues in US$ Millionfor Years 2009 through 2017(includescorresponding Graph/Chart); Table 35: World Historic Review for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$Million for Years 2003 through 2008 (includescorresponding Graph/Chart); Table 36: World 15-Year Perspective for Automated andRapid Microbiological Tests in Non-Clinical Applicationsby Geographic Region - Percentage Breakdown ofRevenues for US, Europe, and Rest of World forYears 2003, 2010 & 2017 (includes correspondingGraph/Chart)
13. THE UNITED STATES: A. Market Analysis; B. Market Analytics
14. EUROPE: A. Market Analysis; B. Market Analytics
14a. FRANCE: A. Market Analysis; B. Market Analytics
14b. GERMANY: A. Market Analysis; B. Market Analytics
14c. ITALY: A. Market Analysis; B. Market Analytics
14d. THE UNITED KINGDOM: A. Market Analysis; B. Market Analytics
14e. SPAIN: A. Market Analysis; B. Market Analytics
14f. RUSSIA: A. Market Analysis; B. Market Analytics
14g. REST OF EUROPE: A. Market Analysis; B. Market Analytics
15. REST OF WORLD: A. Market Analysis; B. Market Analytics
COMPETITIVE LANDSCAPE: Total Companies Profiled: 93 (including Divisions/Subsidiaries - 109)Region/Country Players; The United States; Canada 2; Japan 3; Europe; France; Asia-Pacific (Excluding Japan) 4; Middle-East 2

More Global Point-of-Care Reports

The Global Market for Medical Devices, 3rd. Edition by Kalorama Information
Medical device makers faced a productive but challenging year in 2011. They innovated existing lines, launched new devices and invested in R&D. But they ...

2012 World Hospital and Point-of-Care Coagulation Testing Market Outlook: Facilities, Test Volumes, Sales Forecasts, and Key Player Market Shares by Venture Planning Group
This report provides a worldwide overview of the coagulation testing market, including estimates of facilities performing coagulation tests, as well as test volume and sales ...

Point-of-Care Diagnostics - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018 by GlobalData
Point-of-Care Diagnostics - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018 Summary GlobalData’s new report, “Point-of-Care Diagnostics - Global Pipeline Analysis, Competitive Landscape and Market ...

Global Continuous Glucose Monitoring Device Market 2011-2015 by Infiniti Research Limited
TechNavio’s analysts forecast the the Global Continuous Glucose Monitoring Device market to grow at a CAGR of 11.5 percent over the period 2011–2015. One of ...

Mobile Health Devices and Applications - Global Market Briefing to 2018 by GlobalData
Mobile Health Devices and Applications - Global Market Briefing to 2018 Summary GlobalData’s new report, “Mobile Health Devices and Applications - Global Market Briefing to 2018” provides ...

See all reports like this >>

Automated and Rapid Microbiological Tests

Share this report

Other tasks

Research Assistance

Related Markets

Point-of-Care Reports

Free Alert Me service